GTR Home > Tests > Hereditary Myeloid Malignancy Panel

Overview

Test order codeHelp: 5165

Test name

Help

Hereditary Myeloid Malignancy Panel

Purpose of the test

Help

This is a clinical test intended for Help: Diagnosis, Monitoring, Mutation Confirmation, Pre-symptomatic, Risk Assessment, Screening

Condition

Help

37 conditions tested. Click Indication tab for more information.

How to order

Help

•All samples should be shipped via overnight delivery at room temperature. •No weekend or holiday deliveries. •Label each specimen with the patient’s name, date of birth and date sample collected. •Send specimens with complete requisition and consent form, otherwise, specimen processing may be delayed.
Order URL Help: http://dnatesting.uchicago.edu/submitting-sample

Specimen source

Buccal swab
Cord blood
Fibroblasts
Peripheral (whole) blood
Saliva
Skin

Methodology

Help
Molecular Genetics
DDeletion/duplication analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
CSequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)

Summary of what is tested

85 genes and variants. Click Methodology tab for more information.

Genes

Clinical utility

Help

Establish or confirm diagnosis

Citations
  • 1. Churpek, J.E., et al., Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma, 2013. 54(1): p. 28-35. 2. Bannon, S.A. and C.D. DiNardo, Hereditary Predispositions to Myelodysplastic Syndrome. Int J Mol Sci, 2016. 17(6). 3. Babushok, D.V., M. Bessler, and T.S. Olson, Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leuk Lymphoma, 2016. 57(3): p. 520-36. 4. Owen, C., M. Barnett, and J. Fitzgibbon, Familial myelodysplasia and acute myeloid leukaemia--a review. Br J Haematol, 2008. 140(2): p. 123-32. 5. Babushok, D.V. and M. Bessler, Genetic predisposition syndromes: when should they be considered in the work-up of MDS? Best Pract Res Clin Haematol, 2015. 28(1): p. 55-68. 6. Arber, D.A., et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leuke

Clinical validity

Help

Not provided

Test services

Help
  • Clinical Testing/Confirmation of Mutations Identified Previously
  • Confirmation of research findings
  • Custom Prenatal Testing
  • Custom mutation-specific/Carrier testing

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Support Center